During 2003, the Company expects to begin a proof-of-principle study to evaluate Xyrem for symptomatic treatment of Fibromyalgia Syndrome (FMS), a chronic condition that is estimated to affect as many as six million individuals in the United States. Fibromyalgia Syndrome is characterized by widespread pain in joints, muscles, tendons, and other soft tissues. Other symptoms include persistent fatigue, headaches, cognitive or memory impairment, morning stiffness and non-restorative sleep. The cause of fibromyalgia is unknown, although an imbalance in growth hormone production may play a role. Studies have demonstrated improvement in symptoms in FMS patients given growth hormone. In addition to increasing restorative sleep, Xyrem may be a growth hormone secretogogue and may therefore produce symptomatic relief. The Company does not expect results from this proof-of-principle FMS study until the second half of 2004.